(MedPage Today) — CHICAGO — Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients helped delay serious outcomes in the ZENITH trial.
Among 172 patients, the drug reduced the…
Source link : https://www.medpagetoday.com/meetingcoverage/acc/114911
Author :
Publish date : 2025-04-01 14:58:00
Copyright for syndicated content belongs to the linked Source.
